Tuesday, May 23, 2000

7:00-8:00AM		ISPOR FACULTY NEWTWORKING GROUP BREAKFAST (open invitation)
7:00-8:00AM		ISPOR INSTITUTIONAL COUNCIL BREAKFAST(invitation only)
8:00-8:30AM		INCOMING PRESIDENTIAL ADDRESS Jon C. Clouse MS, Executive Vice President, Ingenix Pharmaceutical Services, Eden Prairie, MN, USA and ISPOR 1999-2000 President-elect
8:30-10:00AM		SECOND PLENARY SESSION Health Care Delivery and Financing in the New Millennium Moderator: Bryan Luce PhD, MBA, Senior Research Leader & CEO, MEDTAP International, Bethesda, MD, USA and ISPOR 1999-2000 President "The 21st Century: Are We Finally Ready for Health Care Quality?" William L. Roper MD, MPH, Dean, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA "Is There Life After Capitation? The US Health Care System After the Managed Care Revolution" JD Kleinke MSB, President, Health Strategies Network, Denver, CO, USA
10:00-10:30AM		VIEWING OF POSTER PRESENTATIONS & EXHIBITS IN EXHIBIT AREA
10:00-10:30AM		CONTRIBUTED PODIUM PRESENTATIONS
		PRODUCTIVITY / INDIRECT COSTS
	ICP1	INCORPORATING MEASUREMENT OF INDIRECT COSTS IN THE EVALUATION OF AN ASTHMA HEALTH MANAGEMENT PROGRAM Ershoff DH, Buchner DA, Integrated Therapeutics Group, Schering-Plough, Kenilworth, NJ, USA
	ICP2	THE RELATIVE EFFECTIVENESS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) AND TRICYCLIC ANTIDEPRESSANTS (TCAS) IN REDUCING WORKER ABSENTEEISM Treglia M1, Neslusan C2, 1Eli Lilly and Company, Indianapolis, IN, USA; 2The MEDSTAT Group Inc., Washington, DC, USA
	ICP3	FACTORS INFLUENCING PATIENT WILLINGNESS TO PAY FOR DIABETES DISEASE STATE MANAGEMENT PROGRAMS Barner JC, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA
	ICP4	HEALTH STATE PREFERENCES IN DIABETIC PERIPHERAL NEUROPATHY Devine EB1, Sullivan SD1, Lew DP2, Veenstra DL1, 1Department of Pharmacy, University of Washington, Seattle, WA, USA; 2Roche Global Pharmacoeconomic Group, Palo Alto, CA, USA
		COST ANALYSES
	CAN1	COMPARISON OF COSTS OF ASTHMA TREATMENT BETWEEN PATIENTS TREATED WITH ANTI-INFLAMMATORIES VERSUS BRONCHODILATORS Huse DM1, Russell MW1, Weiss ST23, Hartz SC1, 1ICSL Healthcare Research, Burlington, MA, USA; 2Channing Laboratory, Brigham and Women's Hospital, Boston, MA, USA; 3Harvard Medical School, Boston, MA, USA
	CAN2	SHORTER HOSPITAL LENGTH OF STAY FOR CORONARY ANGIOPLASTY PATIENTS WHO RECEIVE ABCIXIMAB VERSUS EPTIFIBATIDE OR TIROFIBAN Lage MJ1, Barber BL2, Scherer J2, McCollam P2, 1Miami University, Oxford, OH, USA; 2Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, IN, USA
	CAN3	BASELINE COST OF ILLNESS OF PARKINSON'S DISEASE IN A LARGE HEALTHCARE PLAN Heaton AH, Martin SL, Littlefield RS, Prime Therapeutics Inc., Eagan, MN, USA
	CAN4	IS PRIOR COMMUNITY ANTIBIOTIC TREATMENT OF PATIENTS HOSPITALISED WITH LOWER RESPIRATORY TRACT INFECTION ASSOCIATED WITH REDUCED IN-HOSPITAL MORTALITY AND LENGTH OF STAY? Steinke D, Donnan P, MacDonald T, Davey P, Medicines Monitoring Unit, Ninewells Hospital, Dundee, Scotland
		COST-EFFECTIVENESS / COST BENEFIT ANALYSES (SESSION I)
	CEB1	ECONOMIC EVALUATION OF REBOXETINE FOR TREATING MAJOR DEPRESSION Sheriff SK1, Levaux HP1, Villa KF1, Schonfeld WH1, Rowland C2, Williamson TE2, 1The Lewin Group, San Francisco, CA, USA; 2Pharmacia & Upjohn, Peapack, NJ, USA
	CEB2	COST-EFFECTIVENESS OF MENINGOCOCCAL VACCINE IN THE U Brown RE1, Sorensen S1, Batista C1, Nuijten M2, 1MEDTAP International Inc., Bethesda, MD, USA; 2MEDTAP International Inc., Amsterdam, The Netherlands
	CEB3	COST-EFFECTIVENESS OF PREVENTION OF CORONARY HEART DISEASE (CHD) WITH SIMVASTATIN IN POLAND Kuzniar J, Orlewska E, Hermanowski T, Romanczuk W, Splawinski J, Institute of Drugs, Warsaw, Poland
	CEB4	THE COST EFFECTIVENESS OF FIXED-DOSE COMBINATION OF DICLOFENAC AND MISOPROSTOL IN PREVENTION OF NSAID-INDUCED ULCERS IN RHEUMATOID ARTHRITIS PATIENTS IN POLAND Orlewska E, Unimed Centre for Pharmacoeconomics, Warsaw, Poland
		DRUG UTILIZATION / COMPLIANCE
	DUC1	DRUG UTILIZATION OF CISAPRIDE AND CONTRAINDICATED DRUGS IN A US MANAGED CARE POPULATION Guo JJ1, Jones JK1, Fife D2, Curkendall S1, Goehring E1, She D1, 1The Degge Group, Ltd., Arlington, VA, USA; 2Janssen Pharmaceutica, Titusville, NJ, USA
	DUC2	INSURANCE CLAIMS COSTS FOR OVERACTIVE BLADDER IN ADULTS Zhou Z1, Jensen GA2, 1Greenstone Healthcare Solutions, Inc., Kalamazoo, MI, USA; 2Institute of Gerontology and Department of Economics, Wayne State University, Detroit, MI, USA
	DUC3	SMOKING CESSATION SUCCESS RATES WITH DRUG THERAPY IN A SAMPLE OF MEDICAID PATIENTS Fincham JE1, Braman KS2, McNees GE1, 1Kansas Medicaid DUR Program, Kansas University, School of Pharmacy, Lawrence, KS, USA; 2State of Kansas Medicaid Health Care Delivery Systems and Policy, Topeka, KS, USA
	DUC4	HIGH USERS OF ß2 AGONISTS: ARE MEDICAID RECIPIENTS BEING TREATED ACCORDING TO NATIONAL ASTHMA GUIDELINES? Reddy P1, Kelly E1, Kophazi M2, Geary E3, Markelon J1, Welter K1, 1Pharmacy School, University of Connecticut, Storrs, CT, USA; 2Health Information Design Inc., Auburn, AL, USA; 3Connecticut Medicaid Department, Hartford, CT, USA
12:00-1:00PM		LUNCH, EXHIBITS & POSTER PRESENTATION VIEWING
1:00-2:30PM		ISSUE PANELS 5-8 (4 concurrent discussions) Use and Abuse of Administrative Data: Selection Bias in Retrospective Research Discussion Leader: J. Michael Sprafka MPH, PhD, Epidemiology and Pharmacoeconomics, Proctor & Gamble, Mason, OH, USA Extrapolating from Efficacy to Effectiveness: Issues and Controversies Discussion Leader: Clifford Goodman PhD, Senior Scientist, Medical Technology, The Lewin Group, Falls Church, VA, USA Cost-Effectiveness vs. Budgetary Impact: Breaking Down the Silos Discussion Leader: Joshua Ofman MD, Vice President of Research, Zynx Health Inc, Beverly Hills, CA, USA Evolving Issues in Prescription Drug Coverage Discussion Leader: Patricia Deverka MD, MS, Vice President, Outcomes Measurement and Performance Assessment, Merck-Medco Managed Care, LLC, Department of Medical Affairs, Franklin Lakes, NJ, USA
2:30-3:30PM		VIEWING OF CONTRIBUTED POSTER PRESENTATIONS, SESSION 2
3:30-4:30PM		CONTRIBUTED WORKSHOPS (concurrent presentations)
	WW17	CEA VS CBA: DOES THE CHOICE MATTER IN PRACTICE? Bala MV1, Zarkin GA2, Mauskopf JA2, 1Centocor, Inc., Malvern, PA, USA; 2Research Triangle Institute, Research Triangle Park, NC, USA
	WW18	THE PROMISE AND CHALLENGE OF PHARMACY BASED RISK ADJUSTERS Fishman P1, Goodman MJ2, Hornbrook MC3, Meenan R3, 1Center for Health Studies, Group Health Cooperative of Puget Sound, Seattle, WA, USA; 2HealthPartners Research Foundation, Minneapolis, MN, USA; 3Center for Health Research, Kaiser Permanente, Northwest Region, Portland, OR, USA
	WW19	METHODS FOR CROSS-CULTURAL ADAPTATION OF HEALTH OUTCOMES MEASURES Eremenco S1, Chang C-H12, Lent L1, Cella D12, 1Evanston Northwestern Healthcare, Evanston, IL, USA; 2Northwestern University, Evanston, IL, USA
	WW20	METHODOLOGIES FOR DEALING WITH UNOBSERVED CONFOUNDERS: PROPENSITY SCORE, INSTRUMENTAL VARIABLES, TWO-STAGE METHOD OF MOMENTS Terza J1, Neslusan C2, Treglia M3, 1Department of Economics, Penn State University, University Park, PA, USA; 2The MEDSTAT Group, Washington, DC, USA; 3Eli Lilly and Company, Indianapolis, IN, USA
	WW21	DISEASE-SPECIFIC UTILITY MEASUREMENT Torrance G12, Rosner A2, Keresteci M2, 1McMaster University, Hamilton, ON, Canada; 2Innovus Research Inc., Burlington, ON, Canada
	WW22	COMMUNICATION STRATEGIES FOR HEALTH OUTCOMES DATA Evans C1, Crawford B1, Hayes J2, Cavallo F3, 1MAPI Values, Boston, MA, USA; 2Adelphi Group, New York, NY, USA; 3MediCine, New York, NY, USA
	WW23	COST DEVELOPMENT: THE GOOD, THE BAD AND THE UGLY O'Brien J, Caro Research, Concord, MA, USA
4:30-5:30PM		CONTRIBUTED WORKSHOPS (concurrent presentations)
	WW24	METHODOLOGICAL CHALLENGES IN CONDUCTING ECONOMIC EVALUATIONS IN CHILDREN Ungar W, Santos M, Population Health Sciences, The Hospital for Sick Children Research Institute, Toronto, ON, Canada
	WW25	BEYOND THE STATIC: EPIDEMIOLOGICAL MODELING IN PHARMACOECONOMIC STUDIES FOR INFECTIOUS DISEASES Richter A, Mauskopf JA, Research Triangle Institute, Research Triangle Park, NC, USA
	WW26	CURRENT METHODS IN RETROSPECTIVE DATABASE RESEARCH Thompson D, McGarry L, Innovus Research Inc., Medford, MA, USA
	WW27	BUDGET IMPACT MODELS FOR PHARMACY DECISION MAKING: A RETROSPECTIVE LOOK AT PERFORMANCE Wright A, Pierson P, Crowley P, Advance Paradigm, Hunt Valley, MD, USA
	WW28	RASCH MODELING IN CROSS-CULTURAL VALIDATION OF INSTRUMENTS Marquis P1, de la Loge C1, Crawford B2, 1MAPI Values, Lyon, France; 2MAPI Values, Boston, MA, USA
	WW29	CAPTURING REHOSPITALIZATIONS FOR ECONOMIC SUBSTUDIES OF MULTICENTER, RANDOMIZED CLINICAL TRIALS: THE SYMPHONY EXPERIENCE Davidson-Ray L1, Hakim Z2, Mark D1, 1Outcomes Research and Assessment Group, Duke Clinical Research Institute, Durham, NC, USA; 2Roche Global Pharmacoeconomic Research, Palo Alto, CA, USA
	WW30	LEVERAGING HEALTH PLAN INFORMATION SYSTEMS TO EVALUATE THE EFFECTIVENESS OF EDUCATIONAL OUTREACH PROGRAMS Long S, Hatzmann M, The MEDSTAT Group, Inc., Washington, DC, USA
5:30-7:30PM		ISPOR MEDICAL DEVICE TECHNOLOGY FORUM Organized by the ISPOR Medical Device Technology Council (Alexandra Clyde, Medtronic, Minneapolis, MN, USA; Eileen Helzner MD, Johnson & Johnson, Titusville, NJ, USA; Candace Littell, C.L. Littell & Associates, Inc, Woodstock, VA, USA; Randel Richner, Boston Scientific Corporation, Natick, MA, USA)
5:30-5:45PM		Introductions and Medical Device Technology Forum Objectives Presented by: Eileen Helzner MD, Vice President, Worldwide Clinical Development & Outcomes Research, Johnson & Johnson, Titusville, NJ, USA
5:45-6:15PM		Overview of Medical Device Technology Presented by: Annetine Gelijns PhD, Associate Professor, Surgical Science & Public Health, and Director, InCHOIR, Columbia University, New York, NY, USA
6:15-6:45PM		Unique Challenges for Medical Device Outcomes Research Presented by: Stacey Ackerman PhD, Principal, Covance Health Economics and Outcomes Services, Inc., Washington, DC, USA
6:45-7:15PM		Addressing the Specific Needs of Medical Device Outcomes Research
7:15-7:30PM		Panel Discussions and Next Steps
5:30-7:30PM		ISPOR STUDENT FORUM Introduction Mohamed A. Omar RPh, ISPOR Founding Chair, Student Network Group, University of Texas, Austin, TX, USA Welcome Bryan R Luce PhD, MBA, ISPOR 1999-2000 President, Medtap International, Bethesda, MD, USA ISPOR Student Awards Kent Summers RPh, PhD, Eli Lilly and Company, Indianapolis, IN, USA, and ISPOR Awards Committee Chair ISPOR Student Chapter Reports Student Discussions Guest Presentations "How To Give Winning Presentations" Speaker: Jean Paul Gagnon PhD, Director Of Health Policy, Aventis Pharmaceuticals Inc., Kansas City, MO, USA "Health Outcomes Research in the Pharmaceutical Industry" Speaker: Zeba Khan MS, PhD, Senior Outcomes Research Scientist, Glaxo Wellcome Research and Development, Research Triangle Park, NC, USA
5:30-7:30PM		PHRMA HEALTH OUTCOMES COMMITTEE MEETING Mission, current & past activities including 1999 FDA Workshop results will be presented. 2000 initiatives in productivity measurement will be discussed. This meeting is open to all PhRMA member pharmaceutical company employees.
5:30-7:30PM		VALUE IN HEALTH EDITORIAL ADVISORY BOARD MEETING (invitation only)
7:30-9:00PM		VALUE IN HEALTH EDITORIAL ADVISORY BOARD RECEPTION (invitation only)
7:30-9:00PM		STUDENT RECEPTION
7:30-9:00PM		MEDICAL DEVICE TECHNOLOGY RECEPTION
7:30-9:00PM		QUALITY-OF-LIFE SPECIAL INTEREST GROUP MEETING AND RECEPTION (open invitation)
7:30-9:00PM		MEETINGS OF THE ISPOR TASK FORCES ON GOOD RESEARCH PRACTICES/CODE OF ETHICS/USE OF ECEONOMIC INFORMATION IN HEALTHCARE DECISION-MAKING/MEDICAL INFORMATION ACCESS
9:00-12:00AM		"TEXAS STOMP" PARTY